Helping Hand: A Guide To The New UK Consultations On No-Deal Brexit Regs
Executive Summary
With just over three weeks to provide input on the UK's proposed regulatory response to the prospect of a no-deal Brexit, Medtech Insight unravels key messages from the four documents issued by the Medicines and Healthcare products Regulatory Agency (MHRA), condensing 127 pages into the main points to aid industry in providing feedback. There's no time to waste for those wishing to influence the outcome.
You may also be interested in...
EU Regulatory Roundup, October 2018: Regs 'On Track,' First NB Designations On Way, While UK Prepares For No-Deal Brexit
The European Commission has been much more vocal this month. Its message is upbeat. Despite what industry is saying about delays, logjams and products being forced off the market, it claims to be "on track" for timely implementation of the EU's new Medical Device and IVD Regulations. That and more, in top EU regulation stories from October.
Brexit + MDR Equals Little Certainty For UK And EU Medtech Groups
Medtech stakeholders were reminded recently at the UK's largest regulatory forum that even those willing to make the best of Brexit are still working in the dark. The lack of useful government outreach is frustrating most efforts to secure business continuity. And that is without factoring in the huge regulatory changes that the EU's twin medical device regulations – the MDR and IVDR – will bring.
MHRA Admits UK Medtechs Exposed To Risks As It Consults On Brexit No-Deal Impact
The UK Medicines and Healthcare products Regulatory Agency is now consulting, in detail, on what a no-deal Brexit could look like and how it would impact manufacturers and the MHRA itself. Companies have less than four weeks to respond.